Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Recruiting · Phase 1 · NCT05245500
Conditions: Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor, Pancreatic Adenocarcinoma, Advanced Solid Tumor
At a glance
- Research payments reported, 2025
- $6.1M
- U.S. investigators named
- 22
- Sites paid
- 18
- Planned or actual enrollment
- 336
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- MRTX1719 (drug)
- Dates
- Started 2022-06-09; completion 2027-12-10
- Results posted
- Not yet
This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
From ClinicalTrials.gov, last updated 2026-09-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $6.1M in research payments for this study in 2025 (22 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Tanios S. Bekaii-saab, M.D. Hematology & Oncology · Scottsdale, AZ
- Jason Henry, M.D Internal Medicine · Denver, CO
- Robert M. Jotte, MD Hematology & Oncology · Lone Tree, CO
- Hani M. Babiker, MD Hematology & Oncology · Jacksonville, FL
- Cesar A. Perez Batista, M.D. Medical Oncology · Orlando, FL
- Pasi Antero Janne, MD PHD Medical Oncology · Boston, MA
- Sreenivasa Chandana, MD Hematology & Oncology · Grand Rapids, MI
- Ben George, M.D. Medical Oncology · Rochester, MN
- Konstantinos Leventakos, M.D. Medical Oncology · Rochester, MN
- Shetal A. Patel, M.D., PH.D. Medical Oncology · Chapel Hill, NC
- Kristen R. Spencer, D.O. Medical Oncology · New Brunswick, NJ
- Kathryn C. Arbour, M.D. Medical Oncology · New York, NY
- Richard M. Zuniga, MD Hematology & Oncology · Babylon, NY
- Elizabeth J. Davis, MD Medical Oncology · Nashville, TN
- Melissa L. Johnson, MD Medical Oncology · Nashville, TN
- Salwan S. Al Mutar, M.D Medical Oncology · Dallas, TX
- Kyriakos P. Papadopoulos, M.D. Hematology & Oncology · San Antonio, TX
- Andrew S. Paulson, MD Medical Oncology · Dallas, TX
- Donald A. Richards, MD Medical Oncology · Tyler, TX
- Jordi Rodon, MD Medical Oncology · Houston, TX
- Alexander I. Spira, M.D. Medical Oncology · Fairfax, VA
- Mandana Kamgar, M.D. Hematology & Oncology · Milwaukee, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Mayo Clinic Sports Medicine $1.3M
- Dana-Farber Cancer Institute $1.0M
- Sarah Cannon Research Institute, Llc $827,023
- Medical College of Wisconsin, Incorporated $630,814
- Next Oncology $360,338
- Memorial Sloan-Kettering Cancer Center - Cancer $341,997
- South Texas Accelerated Research Therapeutics, Llc $304,697
- The Start Center for Cancer Care $291,942
- Mayo Clinic Jacksonville $272,522
- Mayo Clinic Hospital, AZ $183,935
- Us Oncology Res Llc $107,009
- Ut MD Anderson Cancer Center $106,986
- NYU Langone Hospitals - Tisch Hospitals Clinical Labs $72,982
- North Shore Hematology/oncology Associates, P C $64,005
- Vanderbilt University Medical Center, TN $55,786
- The University of North Carolina at Chapel Hill $50,984
- University of Texas Southwestern $40,838
- Start Midwest $14,108
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.